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Overexpressed somatic alleles are
enriched in functional elements in
Breast Cancer
Paula Restrepo1,2, Mercedeh Movassagh3, Nawaf Alomran2,4, Christian Miller2, Muzi Li2,4,
Chris Trenkov2, Yulian Manchev2, Sonali Bahl1, Stephanie Warnken 5, Liam Spurr1,2, Tatiyana
Apanasovich6, Keith Crandall 5, Nathan Edwards4 & Anelia Horvath 1,2,6,7
Asymmetric allele content in the transcriptome can be indicative of functional and selective features
of the underlying genetic variants. Yet, imbalanced alleles, especially from diploid genome regions,
are poorly explored in cancer. Here we systematically quantify and integrate the variant allele fraction
from corresponding RNA and DNA sequence data from patients with breast cancer acquired through
The Cancer Genome Atlas (TCGA). We test for correlation between allele prevalence and functionality
in known cancer-implicated genes from the Cancer Gene Census (CGC). We document significant allelepreferential expression of functional variants in CGC genes and across the entire dataset. Notably, we
find frequent allele-specific overexpression of variants in tumor-suppressor genes. We also report a
list of over-expressed variants from non-CGC genes. Overall, our analysis presents an integrated set
of features of somatic allele expression and points to the vast information content of the asymmetric
alleles in the cancer transcriptome.
The cancer phenotype is largely driven by somatic mutations, whose carcinogenic effects are ultimately intervened by the transcription process1–3. As a mediator between genotype and phenotype, the tumor transcriptome
reflects both advantage- selective pressure, and direct effects of the mutations on the transcription process. Hence,
the tumor transcriptome is highly informative about the somatic functionality, especially through allele-specific
approaches that can confine expressed structures to particular mutant alleles1–4.
Several studies have explored the allele-specific transcriptional landscape of cancer1, 5–10. Preferentially
expressed alleles are reported to play a role in epithelial ovarian cancer7, as well as in microRNA-implicated carcinogenesis, an example of which is miR-31 dysregulation in lung cancer8. Imbalanced allele expression can be
caused by both large chromosomal alterations, such as copy number alterations (CNAs), and single nucleotide
somatic mutations1.
Nucleotide somatic mutations can affect the transcriptome through alteration of regulatory, splicing, or
expression-rate modifying sites. Such effects commonly manifest in cis-fashion and directly impact the transcript
abundance of the mutation bearing allele1, 11, 12. Mutations can also indirectly imbalance the allele content through
changing the protein functions to either advance or impair the tumor growth. Functional mutations that provide
selective advantage are referred to as drivers, and they are commonly targeted by either positive or negative selection forces to retain or deplete the growth-affecting allele13–16. Accordingly, somatic allele imbalance, including
the extremes of loss or over-expression, can indicate tumorigenic functionality.
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Figure 1. Major steps of the analysis of allele distribution for somatic variants in our dataset. VR:D was analyzed
for correlation with different functional mutations groups in oncogenes, tumor suppressors, and the rest of
the genes. SOM-E and SOM-L variants were compared with the rest of the somatic mutations for predicted
pathogenicity and location in functional motifs such as transcription and splice factor binding sites, and highly
preserved sequences.

Expression imbalance of point mutations is particularly informative for regions with no CNAs, where
potential effects on the transcription can be directly linked to the underlying nucleotide change14. Therefore,
quantitative integration of allele signals between same-source DNA and RNA is instrumental for tracking
chromosome-of-origin effects. The latter, in turn, can be used to search for new genes whose allele behavior follows the pattern of known cancer drivers and is thus indicative for potential carcinogenicity. Therefore, the few
studies that quantitatively integrate allele abundance from matching DNA and RNA sequencing sources are very
informative10.
Herein, we apply a software that we recently developed – RNA2DNAlign9 – to systematically quantify the allele
expression of somatic variants in breast cancer samples from The Cancer Genome Atlas (TCGA). RNA2DNAlign
counts variant and reference sequencing reads derived from compatible RNA and DNA datasets, and tests for
allelic imbalance; it also calls positions with extreme allele distributions, including somatic over-Expression
(SOM-E) or loss (SOM-L). We compute and compare the somatic variant allele fraction (VAF) of mutations
in genes from the Cancer Gene Census (CGC)17 to those in the rest of the genes in our samples. We also report
a list of non-CGC genes with over-expressed somatic variants. Overall, we present an integrated set of somatic
allele-specific expression features, in the context of their potential underlying functionality.

Results

Strategy. Our strategy was to first systematically quantify the variant allele fraction of the tumor RNA
(VAF{tRNA}), and then to assess for correlation between RNA allele asymmetry and functional features (Fig. 1).
Somatic variants (SOM) with a bi-allelic signal in the tumor DNA and a mono-allelic signal in the tumor
RNA were classified as SOM-L (VAF{tRNA} ~ 0) or SOM-E (VAF{tRNA} ~ 1; Fig. 2). We assess both absolute
VAF{tRNA}, and relative to VAF{tDNA}, for which we introduce the expression VR:D = VAF{tRNA}:VAF{tDNA}.
We note that through accounting for the VAF{tDNA}, VR:D reflects the overall genome composition of the sample,
including the contribution from large rearrangements, and admixture with non-tumor genomes (i.e. the sample
purity). First, we analyzed the allele distribution for mutations in known oncogenes and tumor suppressors from
CGC. We evaluated VAF{tRNA} and VR:D for correlation with functional features including conservation, predicted pathogenicity, and location in critical sequence motifs. Next, we assessed these features, in the context of
their allelic expression, in the non-CGC dataset, and highlighted variants whose somatic allele patterns follow
functionality-associated allele behavior of known cancer drivers.
Overall dataset characteristics. A total of 1238 (1139 unique) mutations in 921 genes, from which 68
were listed in CGC, satisfied the requirements for our analysis (Supplementary Table 1 and Supplementary
Figure 1). Between 7 and 51 somatic point mutations in expressed coding regions were assessed per individual sample. Most of the mutations (94%) were singletons (present in only one sample), whereas 44 mutations
were seen in 2, 12 in 3, 4 in 4, 2 in 5, and one mutation each was found in 6 and 7 different samples. Notably,
all non-singleton mutations shared similar allele expression status across the different samples. A total of 437
somatic mutations (38.3%) were not expressed at all in the transcriptome (SOM-L), and 73 mutations (4.9%)
were over-expressed (SOM-E). The analysis of the variant allele fraction showed an overall positive correlation
between VAF{tDNA} and VAF{tRNA} (Spearman correlation r = 0.38, Fig. 3A–C). The functional distribution
of the predicted consequences on the protein, and the intersection with their allele-expression status is presented
on Fig. 3D. The missense, non-coding and stop-codon variants showed clearly different patterns of VR:D with a
higher VR:D in the missense mutations, as compared to the non-coding and stop-codon variants (p = 0.0004,
Kruskal-Wallis test18, Fig. 3E). Notably, we observed distribution towards higher VR:D of the variants predicted to
be pathogenic through FATHMM (Functional Analysis Through Hidden Markov Models), Fig. 3F19, 20.
CGC genes somatic allele expression: overall features. The 68 known cancer driver genes collectively
contained 103 (88 unique) somatic mutations qualifying for the analysis (Supplementary Table 2)17. Mutations
in PIK3CA, MITF, ACVR2A, CLIP1, and TCEA1 were called in more than one sample. In this gene-set, we called
10 SOM-E variants: seven missense substitutions, two synonymous variants, and, notably, the stop-codon R63X
SCienTifiC RePOrTs | 7: 8287 | DOI:10.1038/s41598-017-08416-w
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Figure 2. IGV visualization of somatic mutations that are over-expressed (SOM-E, middle) or under-expressed
(SOM-L, right) compared to expected allele distribution for a germline heterozygote variant (left); the
heterozygosity is reflected through color-coding of the summary flag on the top of each panel. The gray lines
represent reads, and the colored letters show differences from the reference.

in CDH1. Of note, four of the SOM-E missense substitutions were called in TP53 (See Supplementary Table 2). A
higher number - 25 - SOM-L variants were completely absent from the transcriptome in the CGC dataset.
Several noticeable observations were made in the CGC subset. First, different VR:D distribution was observed
in the CGC variants as compared to the rest of the dataset (p = 0.02, Kruskal-Wallis test18, Fig. 4A); the difference due to larger proportion of CGC variants with higher allele expression. Second, the CGC missense mutations showed higher allele expression as compared to the missense mutations in the entire dataset (p = 0.03,
Kruskal-Wallis test18, Fig. 4B). Notably, a tendency for higher VR:D was also seen for the stop-codon mutations,
albeit not reaching statistical significance (Fig. 4C). In contrast, the non-coding variants did not show significant differences between the CGC and non-CGC genes (Fig. 4D). Third, we documented positive correlation
between VR:D and predicted pathogenicity assessed by the CADD score (Combined Annotation Dependent
Depletion)21, (Spearman r = 0.25), FATHMM score (Functional Analysis Through Hidden Markov Models)19, 20
(Spearman r = 0.17), and conservation of the position of the somatic mutation as assessed through GERP
(Genomic Evolutionary Rate Profiling, Spearman r = 0.29)22–26. Of note, 21% of the variants in the CGC dataset
modeled through FATHMM as pathogenic have been reported in cancer-based studies17. Collectively, all the
above analyses supported preferential expression of functional alleles in the CGC dataset.
SCienTifiC RePOrTs | 7: 8287 | DOI:10.1038/s41598-017-08416-w
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Figure 3. (A–C) Distribution of VAFtRNA (blue) and VR:D (red) in the subgroups of missense (A), non-coding
(B) and stop-codon variants. The X axis shows the number of variants in each functional category. Positive
correlation is seen in all three mutation groups. (D) Distribution of SOM-E and SOM-L expression status in
regards to predicted effect on the protein function in the entire set, CGC-, and non-CGC variants. (E) VR:D for
non-coding, missense and stop-codon variants across the entire dataset. Clearly different VR:D distribution is
seen among the different functional subtypes, with the missense mutations showing higher VR:D, indicative
for higher allele expression of potentially functional transcripts. (F) VR:D for pathogenic and neutral variants
as predicted by FATHMM. The difference in the distribution is due to the larger proportion of the pathogenic
mutations with higher VR:D.

We then assessed CGC SOM-E and SOM-L mutations in the context of their harboring gene’s function and
mechanism of action. The first noticeable observation was a tendency for over-representation of genes acting
in recessive molecular mode among the SOM-E variants, as opposed to more-frequent dominant mode of
action in the genes bearing SOM-L variants (p = 0.15). Recessive mode is traditionally more often associated
with tumor-suppressive function, while dominant action is reported frequently for oncogenes27. In our study,
SOM-E status appears not to result from a genomic DNA loss, as evident by the tumor DNA’s biallelic signal
(0 < VAF{tDNA} < 1). Both the inhibition of the reference and the enhancement of the mutant allele’s expression
could result in mutant RNA dominance, and these effects could be independent or related to the functionality
of the particular mutation. In the case of the mutations acknowledged as pathogenic in suppressor genes, the
observed overexpression is consistent with mutation-driven allele inactivation, possibly favored by positive selection forces. Such interpretation is in line also with the over-expressed stop-codon R63X in CDH128.
For the SOM-L mutations, whether their expressional loss is linked to potential oncogenic action of the host
gene, is to be determined on per-gene basis. It is important to recognize that many somatic variants are randomly
lost in the tumor transcriptome, and the number of transcribed ones can depend on factors such as Estrogen
Receptor (ER) expression levels1. While it is possible for a SOM-L variant to reside on a lost allele by coincidence,
this is unlikely to explain all SOM-L patterns for variants with known pathogenicity.

Allele expression of somatic mutations in the non-CGC genes.

The integrated features of somatic
allele expression in the non-CGC genes is presented in Supplementary Table 3. We documented concurrent to
the CGC dataset positive correlation between increased allele expression and predicted pathogenicity and conservation scores (Spearman CADD r = 0.11, FATHMM r = 0.12, and GERP r = 0.17 (Supplementary Table 3).
The non-CGC somatic mutations with strong overexpression of the mutation-bearing allele (VAF{tRNA} = 1)
are presented in Table 1. We next assessed the SOM-E variants for location within transcription and splicing
factor binding sites, including analysis for generation of a new binding site outside of known protein - recognizable sequences29. Indeed, 18 out of the 42 non-CGC SOM-E variants positioned outside an existing TFBS were
predicted to generate a new motif recognizable by either transcription or a splicing factor29, 30.
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Figure 4. VR:D in the CGC vs non-CGC genes (A), in missense variants (B), in stop-codon variants (B), and in
non-coding variants.

Next, we reviewed, on a per-gene basis, the current knowledge on the SOM-E genes and their possible implications in cancer. Despite not being listed in the CGC, some of these genes – such as MSH3 and NUAK1 and
NFE2 – have been repeatedly linked to cancer31–33. Notably, more of the SOM-E genes linked to tumor suppressor features (as opposed to oncogenic, p = 3.8e-4, Metacore), which we concurrently observed in the CGC
dataset34, 35. Another striking observation is that 6 of the genes with SOM-E variants –MSH3, RAD51, TCOF1,
TP53BP1, CCNB2, and TOP3B – are directly implicated in DNA damage response and repair36–39 which was also
the top-enriched pathway in the SOM-E dataset (p = 0.05, Metacore). In contrast, the most represented pathway
in the SOM-L group was the immune response (p = 0.05, Metacore). In regards to GO annotations, two differences were detected between the SOM-E and SOM-L groups (Supplementary Figure 2). First, SOM-E variants
were more frequently located in genes encoding receptors and signal transducers, while a higher proportion of
the SOM-L variants resided in structure-supportive genes. In regards to biological processes, the SOM-E group
was enriched in genes involved in response to stimuli.

Discussion

Ultimately, the accurate assessment of the expressed allele fraction is only possible in the context of the corresponding DNA alleles’ content. Herein, we integrate matching RNA and DNA allele fraction from bi-allelic DNA
regions to identify transcriptome-favored alleles. We focus more specifically on somatic point mutations in breast
cancer, which we assess for tumorigenic functionality that can underlie selective transcriptome preference.
The first striking observation from our study is that transcriptome-preferred alleles are enriched in functional features, which are often predicted to alter the original protein function. This correlation was stronger in
the group of genes traditionally acknowledged as tumor suppressors. Tumor suppressors are often lost during
progression, and their loss is considered a contribution to tumor growth40. In our data we see a strong expression preference towards somatically mutated tumor suppressor transcripts, including such bearing a premature
stop-codon. Increased allele expression can be either directly caused by mutation-promoted cis transcription
SCienTifiC RePOrTs | 7: 8287 | DOI:10.1038/s41598-017-08416-w

5

www.nature.com/scientificreports/
Gene

Chr:pos (hg38)

Function

TFBS

SFBS

TMEM51

chr1:15215414C > A

missense

none

none

NBPF3

chr1:21481730T > C

non-coding

none

none to SRp40

EPHA10

chr1:37720517C > T

missense

none

none

KIF26B

chr1:245609349C > G

missense

none to V$LRH1_
Q5_01

none

ILDR1

chr3:122001432G > A

non-coding

V$PPARG_02

none to Sam68, SLM-2

MUC20

chr3:195725818C > T

non-coding

V$CREB1_Q6

hnRNP DL,
SRp55tonone

ZNF518B

chr4:10445288C > G

missense

V$PBX1_02

none

none

hnRNP, HuB,
MBNL1toTIA-1

BBS7

chr4:121828063C > G

non-coding

OTUD4

chr4:145146395G > A

missense

none

SRP4 0to hnRNPA1

SH3RF1

chr4:169136534G > A

non-coding

none

MBNL1 to SRp40

SORBS2

chr4:185589715C > T

missense

none

YB-1 to SAM68

MYO10

chr5:16877688C > G

missense

V$YY1_01

none

MSH3

chr5:80768937T > A

missense

V$STAT3_01

none

PCDHB5

chr5:141136316C > T

non-coding

none

none

GRPEL2

chr5:149351223G > A

missense

V$YY1_02

none

none

SRp20/Nova-1/Nova-2
to none

TCOF1

chr5:150376236C > T

missense

MDN1

chr6:89700782A > T

non-coding

V$SMAD4_Q6_01

none

TNRC18

chr7:5316065C > A

non-coding

none

none

WDR60

chr7:158871385A > G

missense

none

none to SC35,SF2/
ASF,hnRNPA1

FZD3

chr8:28527405G > A

non-coding

none

none

DAPK1

chr9:87706999C > T

missense

V$NFAT_Q6

none

COL27A1

chr9:114309301C > G

missense

none to
V$MYOGENIN_
Q6_01

none

PLCE1

chr10:94270600A > C

missense

none to V$NFAT1_
Q4

SF2/ASF,hnRNPA1 to
none

PDCD11

chr10:103441838A > C

missense

none

YB-1 to SRp-40
none
SRp30c to none

MUC6

chr11:1016406G > A

missense

none to V$NFAT1_
Q4

ACER3

chr11:76861031G > T

missense

none

RAB38

chr11:88175236A > T

missense

V$PPARG_02

none

V$IK3_01

none to HuB,TIA1,SRp40

PHLDB1

chr11:118627958C > T

missense

WNK1

chr12:753666C > G

missense

V$GFI1_01

none

NFE2

chr12:54292991G > A

missense

none to V$BEN_01

none to YB-1,SRp40

NUAK1

chr12:106067839A > T

missense

V$OCT1_06

none

RASAL1

chr12:113114816C > G

missense

V$YY1_01

none

SLITRK6

chr13:85795773C > A

missense

V$SMAD4_Q6_01

SF2/ASF,SRp38,YB-1 to
Sam68

ATP11A

chr13:112858175C > A

missense

V$PAX5_01

none

NYNRIN

chr14:24411385C > G

non-coding

none to V$BEN_01

MBNL1

CLMN

chr14:95203587C > T

missense

none

none to hnRNPI

AHNAK2

chr14:104948892T > C

missense

none

none

RAD51

chr15:40706209C > A

non-coding

V$CEBPB_02

none

CCNB2

chr15:59125011G > A

non-coding

none

none

SULT1A2

chr16:28592021A > G

non-coding

none

SRp30c to none

missense

none to V$GATA_
Q6

none to SLM-2, Sam68

NFATC3

chr16:68190983G > A

MED31

chr17:6651601A > G

non-coding

none

SRp30c to none

CHRNB1

chr17:7447082C > T

non-coding

none

none to ETR-3

ACBD4

chr17:45136583C > T

missense

none

SRp55t to SC35

ABCA7

chr19:1041510G > A

missense

none

none to YB-1, SRp20

LMNB2

chr19:2431813G > A

non-coding

none

SRp55 to SC35
deleted MBNL1
none to Sam68, SLM-2

ZNF676

chr19:22180184G > T

non-coding

none to V$NFAT1_
Q4

ZIM2

chr19:56774836G > T

stop

none to V$DRI1_01

Continued
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Gene

Chr:pos (hg38)

Function

TFBS

SFBS
SLM-2 to
hnRNP,DAZAP1, HuD

MRPL30

chr2:99181122C > A

non-coding

none to V$NFAT1_
Q4

PASK

chr2:241126376C > G

missense

none

ETR-3 to SF2/ASF

TOP3B

chr22:21964200A > T

non-coding

none

hnRNPH1,hnRNPH2
to none

GGA1

chr22:37620258G > A

synonymous

none

ETR-3, SRp30c to
hnRNPH1/2

RIBC2

chr22:45426055G > A

non-coding

none

hnRNP K to SF2/ASF

GRPR

chrX:16123978C > G

missense

none

none

TBC1D25

chrX:48560553C > G

missense

none

none

IGBP1

chrX:70133976C > T

missense

none

MNBL1 to SRp40, SRp55

HTATSF1

chrX:136510164G > C

missense

none

none to SRp20, YB-1

Table 1. SOM-E mutations in non-GCG genes: location within transcription and splicing factor recognizable
motifs.

activation, or/and retention of the mutant allele in the transcriptome via positive selection. Both scenarios infer
functionality and growth-supportive potential. Conforming with that, highly expressed somatic variants, including SOM-E, were more frequently located in highly conserved and predicted to be functional genomic sequences.
Taken together, these data are consistent with gain-of-function mechanism favored by the tumor transcriptome.
An active role of over-expressed variants is also supported by the selection for maintaining the expression of a
complete, translation-ready transcripts, suggesting a possible role of the altered/shortened proteins in the tumor
progression. Indeed, once recognized as tumor suppressors, many of the genes in our SOM-E set, including TP53
are now acknowledged to play more complex roles that include oncogenic action41–44. Both inactivation and altering the protein function can be crucial for the tumor development. Regardless the mechanism of action, the above
observations mark allelic overexpression as a highly informative metric that can be used to outline functionally
enriched somatic datasets.
The proportion of SOM-L alleles in our data is generally consistent with other reports1. Under-expressed
alleles, including SOM-L, also correlated with functional annotations and regulatory motifs, though did not
reach the significance of SOM-E. In contrast to SOM-E, SOM-L variants confer features that imply intolerance
of the transcriptional machinery to the harbored variant. In the absence of CNAs, several mechanisms could
potentially lower allele expression levels of mutation bearing transcripts. A well acknowledged scenario is the
surveillance-driven targeting of transcripts with deleterious variants, the most prominent example of which is
NMD1, 45. A degradation mechanism can also take place where the mutation results in an unstable RNA structure46. Finally, a mutation can destroy a binding site for a transcription or splicing factor, thus directly abolishing
the expression of the underlying alleles14. Additional factors, such as high ER expression levels, are also reported
to correlate with a decreased number of expressed somatic mutations1. Besides the above mutation-focused
mechanisms, SOM-L may result from random under-expression in the tumor transcriptome, and the general
infidelity of cancer transcriptional machinery47, 48. The later confers higher contribution of randomness towards
SOM-L loci, which is likely to dilute functional annotations in this group.
Another striking observation from our analysis is the expression pattern of stop-codon mutations. Several
recent studies have published decreased expression of stop-codon bearing variants in cancer, and have linked it to
NMD1, 49. Notably, in our data we see stop-codon bearing alleles over-represented as compared to the reference.
Whether these expressed RNAs are translated into shorter proteins is subject of further studies, but this possibility
is consistent by the presence of premature stop containing, translation-ready transcripts1. While NMD is knowledgeably impaired in cancer, our data suggests gene-selective NMD actions50–52.
Distinguishing pathogenic mutations from the more prevalent neutral variants constitutes one of the greatest challenges of cancer biology, leading to substantial effort towards developing confident analytic strategies.
Modern methods integrate traditional frequency based approaches with expression abundance, functional effects,
interaction networks and pathway context13, 53–60. Here, we integrate somatic allele fraction with most of the
above strategies and the knowledge on tumor driving mechanisms, and evaluate the potential of asymmetric
allele expression to predict cancer implicated variants. We document distinct allele signatures of cancer drivers at
several levels. First, mutations in known cancer genes from our dataset presented more frequently with extreme
allele patterns. An example is TP53, mutation in which were frequently either over-expressed or lost. Second,
mutations in known cancer-implicated genes presented with higher allele expression. This was also reflected in
the higher percentage of SOM-E variants among the known cancer genes. Third, SOM-E mutation sites were
enriched in conservation and functional motifs. Cumulatively, these findings highlight the SOM-E status as a
potential indicator for cancer-driving functionality. Based on the above, we list the non-CGC genes whose expression status follows the drivers-enriched SOM-E status (see Table 1); albeit not included in the CGC list, some of
these genes have been linked to cancer before and are worth further investigation. In summary, our research illustrates an important correlation between asymmetric alleles and cancer-implicated functionality, and functionality
in general, and underscores the vast information content of our strategy to systematically outline asymmetrically
expressed alleles. This strategy is applicable to all types of cancer and is now enabled by the growing accessibility
of matched DNA and RNA sequence data new tools for their integration and analysis9, 61, 62.
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Methods

TCGA samples selection. We first identified all breast cancer samples for which the following five sets
were available: normal exome, normal transcriptome, tumor exome, tumor transcriptome, and CNA data (segmentation file based on Affymetrix SNPv6 array profiling)12, 60, 63, 64. All these samples had at purity assessed with
at least three of the following five purity estimators: ESTIMATE, ABSOLUTE, LUMP, IHC and the Consensus
Purity Estimation (CPE)65–68. From these, we excluded samples with extensive (more than 3 standard deviations)
number of somatic mutations, possibly due to clustered genomic rearrangements69, 70. The remaining 72 samples
(Supplementary Table 4) were retained for further analysis. We reviewed the pathology reports and retrieved the
available clinical information; data for 41 (57%) of the studied samples was available (See Supplementary Table 4).
The highest proportion of the samples were ductal adenocarcinomas, either ER, or ER/PR positive. We did not
observe any significantly distinguishing somatic expression patterns, which is likely due to the small sample size.
The purity, as assessed by the above-mentioned algorithms, is shown in Supplementary Table 5.
Allele count computation. All the used datasets were generated through paired-end sequencing on
an Illumina HiSeq platform. The aligned to the human genome reference (hg38) sequencing reads (Binary
Alignment Maps,bams) were downloaded from the Genomic Data Commons Data Portal (https://portal.gdc.
cancer.gov/) and processed downstream through an in-house pipeline. Briefly, for both DNA and RNA datasets variants were called using the mpileup module of SAMtools70. The variants were further annotated through
SeattleSeq. 147 (http://snp.gs.washington.edu/SeattleSeqAnnotation147/). The alignments together with the variant calls (.vcf) were processed through RNA2DNAlign. RNA2DNAlign produced variant and reference sequencing reads counts for all the variant positions in all four datasets (normal exome, normal transcriptome, tumor
exome and tumor transcriptome). The read count assessments were visually examined using Integrative Genome
Viewer72. We excluded from further analyses variants which (1) were covered with less than 10 sequencing read
in the tumor DNA or the RNA sequencing data; (2) reside in known imprinted regions, and (3) reside in area
affected by copy number change in the corresponding sample, as defined based on the CNA segmentation file, (4)
were present in the normal DNA or RNA, suggestive for germline origin.
Assessment for allele distribution.

Allele expression rates within a sample were determined through
estimation of the relative abundance of variant over total sequence read counts, expressed as Variant Allele
Fraction (VAF). For each somatic mutation, we computed the VAF = n(var)/(n(ref) + n(var)), for both tumor
RNA (VAF{tRNA}) and tumor DNA (VAF{tDNA}), where n(ref) and n(var) are the counts of the variant and
reference sequencing reads covering the position. To account for allele asymmetries related to DNA, we analyzed VAF{tRNA} in the context of the corresponding VAF{tDNA}. Over-expression of somatic mutations
(SOM-E status) was determined as prevalence of variant sequencing reads in the transcriptome (VAF{tRNA} ~
1), while SOM-L was defined by complete loss of the mutant allele in the transcriptome (VAF{tRNA} ~ 0). All the
VAF{tRNA} values were used in a correlation analyses to search for association with functional features. Overall
VAFs across the studied datasets were illustrated using Circos plots (See Supplementary Figure 1)73.

Functional and enrichment analyses. Functional annotations, conservation scores and modeled pathogenicity were extracted using the SeattleSeq annotation 147 (http://snp.gs.washington.edu/
SeattleSeqAnnotation147/index.jsp). Pathogenicity was modeled using PolyPhen, CADD and FATHMM models,
and Conservation was assessed based on Phast, GREP and Grantham Scores20–26. Gene Ontology categories, pathway enrichment and network analysis were assessed using Metacore (Claritive Analytics). Transcription factor
binding cites were analyzed using TRANSFAC 7.029 and splicing motifs were assessed using SpliceAid230.
Statistics.

SOM, SOM-E and SOM-L variants were called based on a binomial test for variant and reference sequencing read distribution, as previously described9. The distributions of SOM-E and SOM-L across
tumor-suppressors, oncogenes, and the rest of the genes in the datasets, as well as the distribution of functional
elements across SOM, SOM-E and SOM-L, were assessed using the Fisher exact test, Pearson chi-square test,
Kruskal-Wallis rank sum test, linear regression analysis, and the Spearman rank correlation coefficient18, 74, 75.
Yates’s correction for continuity was applied for tests with less than 5 measurements in any category76. The means
of the VAF across different mutation types were compared using Student’s t-test77. P-values below 0.05 were
considered significant. For multiple trials, the significance value was corrected using Benjamini-Hochberg False
Discovery Rate (FDR) technique.
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